drugset / Trial / NCT02183038

Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis

NCT02183038

Phase 2 Completed 390 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess the efficacy and tolerability of Meloxicam once daily dose of 7.5 mg and 15 mg compared with 1100 mg of naproxen sodium in the symptomatic treatment of acute non bacterial pharyngitis or pharyngo-tonsillitis, over a period of 5 days.

Timeline

Start
1998-07
Primary completion
1999-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 7.5 mg
Subject Meloxicam Small molecule 15 mg
Comparator Naproxen Small molecule 1100 mg

Indications